Robert Dee Etherington
Chief Executive Officer bei CLENE INC.
Vermögen: 40 082 $ am 31.03.2024
Profil
Robert Dee Etherington is currently the President, Chief Executive Officer & Director at Clene Nanomedicine, Inc. and Clene, Inc. He is also a Director at BioUtah and Corsair LLC.
Previously, he worked as the Marketing Director at Actelion Pharmaceuticals Ltd.
from 2000 to 2013.
Mr. Etherington completed his undergraduate degree at Brigham Young University in 1990 and obtained an MBA in 1992.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CLENE INC
0,07% | 01.04.2024 | 94 310 ( 0,07% ) | 40 082 $ | 31.03.2024 |
Aktive Positionen von Robert Dee Etherington
| Unternehmen | Position | Beginn |
|---|---|---|
| CLENE INC. | Chief Executive Officer | 01.04.2013 |
| BioUtah | Director/Board Member | 01.06.2016 |
Clene Nanomedicine, Inc.
 Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | Chief Executive Officer | 01.04.2013 |
| Corsair LLC | Director/Board Member | 01.03.2018 |
Ehemalige bekannte Positionen von Robert Dee Etherington
| Unternehmen | Position | Ende |
|---|---|---|
Actelion Pharmaceuticals Ltd.
 Actelion Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, Actelion Pharmaceuticals Ltd. is a Swiss company that develops and distributes molecular weight drugs. The private company is based in Allschwil, Switzerland. | Sales & Marketing | 01.03.2013 |
Ausbildung von Robert Dee Etherington
| Brigham Young University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CLENE INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
| BioUtah | |
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | Health Technology |
Actelion Pharmaceuticals Ltd.
Actelion Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, Actelion Pharmaceuticals Ltd. is a Swiss company that develops and distributes molecular weight drugs. The private company is based in Allschwil, Switzerland. | Health Technology |
| Corsair LLC |
